RE:Updated Report from Noble Capital Markets The latest presentation is helpful too.
To me , the presence in China and the strong demand from China for beta glucan is of huge importance.
The rising demand from China is a major growth driver while CWO could become a takeover target for a Chinese company:
"Total sales of $4,666,000 for the second quarter of 2020 and $8,939,000 for the first six months of 2020 compared to $3,054,000 and $6,251,000 for the comparative periods in 2019. The 43% increase in sales for the first six months is mainly due to a significant increase in sales of avenanthramides as well as an increase in sales of beta glucan to China, compared to the same period in 2019." https://www.globenewswire.com/news-release/2020/08/20/2081403/0/en/Ceapro-Inc-Reports-2020-Second-Quarter-and-Six-Month-Financial-Results-and-Operational-Highlights.html